Ninlaro Maintenance Delays Disease Progression, Death in Myeloma Patients, Phase 3 Trial Shows
Multiple myeloma patients who receive Ninlaro (ixazomib) maintenance after responding to their initial treatment live longer without their disease worsening or returning than patients…